Consistent with the established role of IGF1 in supporting tumour cell proliferation [17], [30], [31], [38], [48], neutralising antibody-directed blockade of the IGF1-R in each of the NSCLC cell lines tested resulted in a partial inhibition of proliferation (Figures 2–4). The gene discussed is IGF1; the disease is non-small cell lung carcinoma.